The Federal Medical and Biological Agency of Russia has initiated the first phase of clinical trials for an innovative vaccine against meningococcus, named MCV-5. According to the agency’s press service, the vaccine’s safety, immunogenicity, and protective properties were established during preclinical trials.
This vaccine is a polysaccharide conjugate formulation that provides protection against five serotypes of meningococcus: A, B, C, W, and Y. The phase I trials will take place at the Eco-Safety Medical Center LLC, involving 50 participants.
The press service highlighted that “most vaccines commonly used globally do not include serotype B.” They noted that the only registered pentavalent vaccine with a similar composition is an American product that received FDA approval at the end of last year.
